简介：AIM:Toinvestigatethebiologicaleffectsofinternalirradiation,andthetherapeuticeffectivenesswasassessedof131I-labeledanti-epidermalgrowthfactorreceptor（EGFR）liposomes,derivedfromcetuximab,whenusedasatumor-targetingcarrierinacolorectalcancermousemodel.METHODS:WedescribedtheliposomesandcharacterizedtheirEGFR-targetedbindingandcellularuptakeinEGFR-overexpressingLS180colorectalcancercells.Afterintra-tumorinjectionsof74MBq（740MBq/mL）131I-antiEGFR-BSA-PCL,weinvestigatedthebiologicaleffectsofinternalirradiationandthetherapeuticefficacyof131I-antiEGFR-BSA-PCLoncolorectalcancerinamaleBALB/cmousemodel.Tumorsize,bodyweight,histopathology,andSPECTimagingweremonitoredfor33dpost-therapy.RESULTS:Therapidradioiodineuptakeof131I-antiEGFR-BSA-PCLand131I-BSA-PCLreachedmaximumlevelsat4hafterincubation,andthe131Iuptakeof131I-antiEGFR-BSA-PCLwashigherthanthatof131I-BSAPCLinvitro.The131Itissuedistributionassayrevealedthat131I-antiEGFR-BSA-PCLwasmarkedlytakenupbythetumor.Furthermore,atissuedistributionassayrevealedthat131I-antiEGFR-BSA-PCLwasmarkedlytakenupbythetumorandreacheditsmaximaluptakevalueof21.0±1.01%ID/g（%ID/gisthepercentageinjecteddosepergramoftissue）at72hfollowingtherapy;thedrugconcentrationinthetumorwashigherthanthatintheliver,heart,colon,orspleen.Tumorsizemeasurementsshowedthattumordevelopmentwassignificantlyinhibitedbytreatmentswith131I-antiEGFR-BSA-PCLand131I-BSA-PCL.Thevolumeoftumorincreased,andtreatmentratewith131I-antiEGFR-BSA-PCLwas124%±7%,lowerthanthatwith131I-BSA-PCL（127%±9%）,131I（143%±7%）,andnormalsaline（146%±10%）.Thepercentagelossesinoriginalbodyweightswere39%±3%,41%±4%,49%±5%,and55%±13%,respectively.Thebestsurvivalandcurerateswereobtainedinthegrouptreatedwith131I-antiEGFR-BSA-PCL.Theanimalsinjec

简介：背景:在中国恶性肿瘤发病率和死亡率排序中,胃癌分居第二和第三位。探索方法简便、敏感性高的非侵入性指标以筛选出胃癌高危人群接受胃镜检查是胃癌普查的有效途径。目的:探讨三叶因子3(TFF3)作为胃癌筛查血清生物学标记物的临床价值。方法:收集宁波市医疗中心李惠利医院2013年7月—2014年1月49例胃癌患者和29名健康体检者的血清标本,采用ELISA法检测血清TFFs浓度,以ROC曲线及其曲线下面积(AUC)分析血清TFF1、TFF2、TFF3对胃癌的诊断性能,并进一步分析三者与胃癌临床病理特征的关系。结果:胃癌组TFF3血清浓度显著高于健康对照组[(43.57±19.49)ng/mL对(29.97±14.20)ng/mL,P<0.01],两组间TFF1、TFF2血清浓度差异无统计学意义(P>0.05)。血清TFF1、TFF2、TFF3诊断胃癌的AUC分别为0.56、0.56和0.83,TFF3诊断性能最高;以33.0ng/mL为TFF3cutoff值,相应敏感性和特异性分别为63.3%和82.8%,预测胃癌风险的OR值为8.27。TFF3血清浓度与胃癌TNM分期、分化程度和淋巴结转移显著相关(P<0.05)。结论:血清TFF3是一个有应用前景的非侵入性胃癌筛查生物学标记物。

简介：目的：探讨兰索拉唑奥曲肽凝血酶三联治疗ICU重症并发上消化道出血的临床效果。方法在我院选取64例确诊为ICU重症并发上消化道出血的患者，随机分为实验组与对照组，每组均为32例。实验组应用兰索拉唑联合奥曲肽凝血酶三联治疗方法，对照组应用兰索拉唑凝血酶治疗的方法，观察两组患者的治疗效果。结果实验组总有效率为93.75%，对照组总有效率为75.00%，两组差异有统计学意义（P〈0.05）。结论采取兰索拉唑联合奥曲肽凝血酶三联治疗能够有效提高ICU重症并发上消化道出血患者的总有效率。